William Blair Analysts Boost Earnings Estimates for CVRx

Key Points

• William Blair has raised its Q3 2025 earnings estimate for CVRx to ($0.48) per share, an improvement from the previous estimate of ($0.49), and maintains a "Strong-Buy" rating on the stock.
• JPMorgan Chase downgraded its price target for CVRx from $15.00 to $7.00, while Cantor Fitzgerald set a higher target of $11.00, reflecting mixed market sentiments on the stock.
• CVRx recently reported a Q2 loss of ($0.57) per share, missing analysts' expectations, despite revenue surpassing estimates at $13.59 million.

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Research analysts at William Blair increased their Q3 2025 earnings per share (EPS) estimates for CVRx in a research report issued on Tuesday, August 5th. William Blair analyst B. Vazquez now expects that the company will post earnings per share of ($0.48) for the quarter, up from their prior forecast of ($0.49). William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx's Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.98) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.66) EPS.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. The firm had revenue of $13.59 million for the quarter, compared to the consensus estimate of $13.22 million.

A number of other brokerages also recently weighed in on CVRX. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $7.00 price objective (down previously from $15.00) on shares of CVRx in a research report on Friday, May 9th. Piper Sandler reduced their price objective on CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $11.00 price target on shares of CVRx in a research report on Tuesday, August 5th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.00.

CVRx Stock Up 5.4%

CVRX stock traded up $0.39 during trading on Thursday, reaching $7.63. 118,061 shares of the company traded hands, compared to its average volume of 327,005. CVRx has a 12 month low of $4.30 and a 12 month high of $18.55. The business has a 50 day simple moving average of $6.90 and a 200 day simple moving average of $9.22. The company has a market capitalization of $199.54 million, a price-to-earnings ratio of -3.63 and a beta of 1.27. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99.

Institutional Investors Weigh In On CVRx

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC purchased a new stake in CVRx during the 1st quarter worth about $28,000. Tower Research Capital LLC TRC boosted its position in shares of CVRx by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock worth $49,000 after acquiring an additional 1,186 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of CVRx by 1,469.3% during the 1st quarter. GAMMA Investing LLC now owns 4,598 shares of the company's stock worth $56,000 after acquiring an additional 4,305 shares in the last quarter. Mount Lucas Management LP acquired a new position in shares of CVRx during the 2nd quarter worth about $30,000. Finally, Quarry LP acquired a new position in shares of CVRx during the 4th quarter worth about $69,000. Hedge funds and other institutional investors own 75.27% of the company's stock.

Insider Activity

In related news, Director Kirk G. Nielsen purchased 10,966 shares of the business's stock in a transaction on Thursday, May 15th. The shares were bought at an average price of $5.45 per share, for a total transaction of $59,764.70. Following the acquisition, the director directly owned 1,910,134 shares in the company, valued at $10,410,230.30. This trade represents a 0.58% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 13.90% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.